Application Detail
Description of Medical Service
Anaplastic lymphoma kinase (ALK) Fluorescence in situ hybridisation (FISH) testing identifies tumours that carry the ALK rearrangement obtained from patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), which is of non-squamous histology or histology not otherwise specified. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for brigatinib for the treatment of patients with the ALK rearrangement.Description of Medical Condition
ALK-positive locally advanced or metastatic NSCLC, which is of non-squamous histology or histology not otherwise specified.Reason for Application
Amendment to MBS itemMedical Service Type
InvestigativePrevious Application Number/s
Not applicableAssociated Documentation
Application Form
-Consultation Survey
-PICO Confirmation
-Assessment Report
-Public Summary Document
Public Summary Document (PDF 329 KB)Public Summary Document (Word 65 KB)